Effects of Dapagliflozin on epicardial and visceral fat in patients with type 2 diabetes and metabolic syndrome.
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 29 Nov 2017 New trial record
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association.